Published July 5, 2013 | Version v1
Journal article

Activation of type 2 cannabinoid receptors (CB2R) promotes fatty acid oxidation through the SIRT1/PGC-1α pathway

  • 1. Department of Endocrinology, First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu Province 210029 (China)
  • 2. Department of Neurology, Jinling Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu Province 210002 (China)

Description

Highlights: •TC, a CB2R specific agonist, stimulates SIRT1 activity by PKA/CREB pathway. •TC promotes PGC-1α transcriptional activity by increasing its deacetylation. •TC increases the expression of genes linked to FAO and promotes the rate of FAO. •The effects of TC in FAO are dependent on CB2R. •Suggesting CB2R as a target to treat diseases with lipid dysregulation. -- Abstract: Abnormal fatty acid oxidation has been associated with obesity and type 2 diabetes. At the transcriptional level, peroxisome proliferator-activated receptor-gamma coactivator 1α (PGC-1α) has been reported to strongly increase the ability of hormone nuclear receptors PPARα and ERRα to drive transcription of fatty acid oxidation enzymes. In this study, we report that a specific agonist of the type 2 cannabinoid receptor (CB2R) can lead to fatty acid oxidation through the PGC-1α pathway. We have found that CB2R is expressed in differentiated C2C12 myotubes, and that use of the specific agonist trans-caryophyllene (TC) stimulates sirtuin 1 (SIRT1) deacetylase activity by increasing the phosphorylation of cAMP response element-binding protein (CREB), thus leading to increased levels of PGC-1α deacetylation. This use of TC treatment increases the expression of genes linked to the fatty acid oxidation pathway in a SIRT1/PGC-1α-dependent mechanism and also drastically accelerates the rate of complete fatty acid oxidation in C2C12 myotubes, neither of which occur when CB2R mRNA is knocked down using siRNA. These results reveal that activation of CB2R by a selective agonist promotes lipid oxidation through a signaling/transcriptional pathway. Our findings imply that pharmacological manipulation of CB2R may provide therapeutic possibilities to treat metabolic diseases associated with lipid dysregulation

Availability note (English)

Available from http://dx.doi.org/10.1016/j.bbrc.2013.05.108

Additional details

Identifiers

DOI
10.1016/j.bbrc.2013.05.108;
PII
S0006-291X(13)00915-7;

Publishing Information

Journal Title
Biochemical and Biophysical Research Communications
Journal Volume
436
Journal Issue
3
Journal Page Range
p. 377-381
ISSN
0006-291X
CODEN
BBRCA9

INIS

Country of Publication
United States
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
45060748
Subject category
S60: APPLIED LIFE SCIENCES;
Descriptors DEI
AMP; CARBOXYLIC ACIDS; ENZYMES; FAO; GENES; HORMONES; LIPIDS; MESSENGER-RNA; METABOLIC DISEASES; OXIDATION; PHOSPHORYLATION; RECEPTORS; TRANSCRIPTION
Descriptors DEC
CHEMICAL REACTIONS; DISEASES; INTERNATIONAL ORGANIZATIONS; MEMBRANE PROTEINS; NUCLEIC ACIDS; NUCLEOTIDES; ORGANIC ACIDS; ORGANIC COMPOUNDS; PROTEINS; RNA

Optional Information

Copyright
Copyright (c) 2013 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.